CODEXIS INC (CDXS) Stock Price, Quote, News and Overview
NASDAQ:CDXS - Nasdaq - US1920051067 - Common Stock - Currency: USD
CDXS Quote, Performance and Key Statistics
2.33
-0.22 (-8.63%)
The current stock price of CDXS is 2.33 USD. In the past year, price decreased by -31.07%.
CDXS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 18.36 | 151.80B | ||
| DHR | DANAHER CORP | 25.37 | 135.27B | ||
| A | AGILENT TECHNOLOGIES INC | 20.88 | 31.61B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 28.61 | 24.05B | ||
| IQV | IQVIA HOLDINGS INC | 12.28 | 24.01B | ||
| WAT | WATERS CORP | 29.77 | 21.10B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.84 | 15.19B | ||
| ILMN | ILLUMINA INC | 25.35 | 13.37B | ||
| RVTY | REVVITY INC | 18.53 | 10.77B | ||
| ICLR | ICON PLC | 9.54 | 10.40B | ||
| QGEN | QIAGEN N.V. | 19.3 | 9.61B | ||
| TEM | TEMPUS AI INC | N/A | 9.21B |
Related stock screener links
About CDXS
Company Profile
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 188 full-time employees. The company went IPO on 2010-04-22. The company is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. The company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. The company is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. The company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Company Info
CODEXIS INC
200 Penobscot Dr
Redwood City CALIFORNIA 94063 US
CEO: John J. Nicols
Employees: 188
Phone: 16504218100
CODEXIS INC / CDXS FAQ
What is the stock price of CODEXIS INC today?
The current stock price of CDXS is 2.33 USD. The price decreased by -8.63% in the last trading session.
What is the ticker symbol for CODEXIS INC stock?
The exchange symbol of CODEXIS INC is CDXS and it is listed on the Nasdaq exchange.
On which exchange is CDXS stock listed?
CDXS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CODEXIS INC stock?
13 analysts have analysed CDXS and the average price target is 7.48 USD. This implies a price increase of 221.03% is expected in the next year compared to the current price of 2.33. Check the CODEXIS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CODEXIS INC worth?
CODEXIS INC (CDXS) has a market capitalization of 193.02M USD. This makes CDXS a Micro Cap stock.
How many employees does CODEXIS INC have?
CODEXIS INC (CDXS) currently has 188 employees.
What are the support and resistance levels for CODEXIS INC (CDXS) stock?
CODEXIS INC (CDXS) has a support level at 2.32 and a resistance level at 2.43. Check the full technical report for a detailed analysis of CDXS support and resistance levels.
Is CODEXIS INC (CDXS) expected to grow?
The Revenue of CODEXIS INC (CDXS) is expected to decline by -8.74% in the next year. Check the estimates tab for more information on the CDXS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CODEXIS INC (CDXS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CDXS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CDXS, evaluating the profitability, health, valuation and growth aspects
- CODEXIS INC (CDXS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CODEXIS INC (CDXS) Sales and EPS estimates to see what analysts future expectations are.
- CODEXIS INC (CDXS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CODEXIS INC (CDXS) Insider and Institutional Ownership to learn about the owners and their transactions.
- CODEXIS INC (CDXS) Stock Chart to make your own analysis
- CODEXIS INC (CDXS) Latest news and press-releases to stay up to date.
Does CODEXIS INC (CDXS) stock pay dividends?
CDXS does not pay a dividend.
When does CODEXIS INC (CDXS) report earnings?
CODEXIS INC (CDXS) will report earnings on 2025-08-06, after the market close.
What is the Price/Earnings (PE) ratio of CODEXIS INC (CDXS)?
CODEXIS INC (CDXS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.99).
What is the Short Interest ratio of CODEXIS INC (CDXS) stock?
The outstanding short interest for CODEXIS INC (CDXS) is 7.04% of its float. Check the ownership tab for more information on the CDXS short interest.
CDXS Technical Analysis
CDXS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CDXS. CDXS may be in some trouble as it scores bad on both profitability and health.
CDXS Financial Highlights
Over the last trailing twelve months CDXS reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS decreased by -6.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -57.77% | ||
| ROE | -150.03% | ||
| Debt/Equity | 0.59 |
CDXS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to CDXS. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 19.37% and a revenue growth -8.74% for CDXS